135 related articles for article (PubMed ID: 37663315)
1. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy.
Tremblay G; Majethia U; Kontoudis I; De Rosendo J
J Health Econ Outcomes Res; 2016; 3(2):180-193. PubMed ID: 37663315
[No Abstract] [Full Text] [Related]
2. Economic evaluation of eribulin as second-line treatment for metastatic breast cancer in South Korea.
Tremblay G; Majethia U; Breeze JL; Kontoudis I; Park J
Clinicoecon Outcomes Res; 2016; 8():485-493. PubMed ID: 27698565
[TBL] [Abstract][Full Text] [Related]
3. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Bagust A; Duarte R; Richardson M; Nevitt S; Boland A; Kotas E; McEntee J; Thorp N
Pharmacoecon Open; 2019 Sep; 3(3):293-302. PubMed ID: 30742256
[TBL] [Abstract][Full Text] [Related]
4. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Wu Y; Dong Z; Wang J; Fang Q
BMJ Open; 2022 Nov; 12(11):e065299. PubMed ID: 36379662
[TBL] [Abstract][Full Text] [Related]
5. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
Lopes G; Glück S; Avancha K; Montero AJ
Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Dranitsaris G; Gluck S; Faria C; Cox D; Rugo H
Clin Ther; 2015 Jan; 37(1):134-44. PubMed ID: 25433768
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and Value-based Pricing of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Low HER2 Expression.
Huang X; Lin D; Lin S; Luo S; Huang X; Deng Y; Weng X; Huang P
Clin Breast Cancer; 2023 Jul; 23(5):508-518. PubMed ID: 37085377
[TBL] [Abstract][Full Text] [Related]
8. Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Greenhalgh J; Bagust A; Boland A; Oyee J; Trevor N; Beale S; Dundar Y; Hockenhull J; Proudlove C; O'Reilly S
Pharmacoeconomics; 2015 Feb; 33(2):137-48. PubMed ID: 25213036
[TBL] [Abstract][Full Text] [Related]
9. Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapy.
Pivot X; Marmé F; Koenigsberg R; Guo M; Berrak E; Wolfer A
Ann Oncol; 2016 Aug; 27(8):1525-31. PubMed ID: 27177860
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Liao M; Jiang Q; Hu H; Han J; She L; Yao L; Ding D; Huang J
J Med Econ; 2019 Jun; 22(6):584-592. PubMed ID: 30808230
[No Abstract] [Full Text] [Related]
11. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.
Kaufman PA; Awada A; Twelves C; Yelle L; Perez EA; Velikova G; Olivo MS; He Y; Dutcus CE; Cortes J
J Clin Oncol; 2015 Feb; 33(6):594-601. PubMed ID: 25605862
[TBL] [Abstract][Full Text] [Related]
12. Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Kazmi S; Chatterjee D; Raju D; Hauser R; Kaufman PA
Breast Cancer Res Treat; 2020 Nov; 184(2):559-565. PubMed ID: 32808239
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Adding Palbociclib as a Second-Line Endocrine Therapy for HR
Zhang Y; Zeng X; Deng H; Ma F; Peng Y; Yi L; Tan C; Peng L
Clin Ther; 2019 Jun; 41(6):1175-1185. PubMed ID: 31104762
[TBL] [Abstract][Full Text] [Related]
15. Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.
Aftimos P; Polastro L; Ameye L; Jungels C; Vakili J; Paesmans M; van den Eerenbeemt J; Buttice A; Gombos A; de Valeriola D; Gil T; Piccart-Gebhart M; Awada A
Eur J Cancer; 2016 Jun; 60():117-24. PubMed ID: 27107326
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women.
Gupta N; Gupta D; Dixit J; Mehra N; Singh A; Krishnamurthy MN; Jyani G; Rajsekhar K; Kalaiyarasi JP; Roy PS; Malik PS; Mathew A; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
Appl Health Econ Health Policy; 2022 Jul; 20(4):609-621. PubMed ID: 35534752
[TBL] [Abstract][Full Text] [Related]
17. Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer.
Twelves C; Awada A; Cortes J; Yelle L; Velikova G; Olivo MS; Song J; Dutcus CE; Kaufman PA
Breast Cancer (Auckl); 2016; 10():77-84. PubMed ID: 27398025
[TBL] [Abstract][Full Text] [Related]
18. Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer.
Zhao Q; Hughes R; Neupane B; Mickle K; Su Y; Chabot I; Betts M; Kadambi A
BMC Cancer; 2021 Jun; 21(1):758. PubMed ID: 34193107
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
McIntyre K; O'Shaughnessy J; Schwartzberg L; Glück S; Berrak E; Song JX; Cox D; Vahdat LT
Breast Cancer Res Treat; 2014 Jul; 146(2):321-8. PubMed ID: 24699910
[TBL] [Abstract][Full Text] [Related]
20. A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes.
Kimura K; Iwamoto M; Tanaka S; Yamamoto D; Yoshidome K; Ogura H; Terasawa R; Matsunami N; Takahashi Y; Nitta T; Morimoto T; Fujioka H; Kawaguchi K; Uchiyama K
Cancer Chemother Pharmacol; 2018 May; 81(5):923-933. PubMed ID: 29594360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
